-
-
-
-
-
-
-
Allarity Therapeutics (ALLR) Appoints James G. Cullem as Interim CEO
-
-
-
-
-
-
-
U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq
-
-
1,188,210 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

